NextCure is charging toward the end of the year with three immuno-oncology clinical trials and what they feel is a distinctly unique approach to using biomarkers to guide their drug-development process.
NextCure University: Transforming the Delivery of Microlearning Programs to Build an Innovative Workforce Focused on Cross Training By Sarah EllinwoodJune 12, 2023 As you navigate your life science career, it’s [….]
NC410 alleviates immunosuppression, remodels collagen to increase T cell infiltration (SOURCE: NextCure) How NextCure Leverages the Unique Biology of LAIR to Treat Different Cancers By Sarah EllinwoodApril 18, 2023 Every [….]
How NextCure is Approaching Women’s Cancers Differently: Perspectives from Three Scientists By Sarah EllinwoodMarch 30, 2023 Breast cancer. Cervical cancer. Ovarian cancer. Uterine cancer. Like many cancers that are out [….]
On International Day, the entire company had a chance to put down their laptops and lab coats for a bit to celebrate their remarkable diversity.
For NextCure, a fast-growing, publicly-traded (Nasdaq: NXTC) clinical-stage biotech located in Beltsville, Maryland, choosing to invest in and build capabilities in-house aligned with its mission to serve patients that do not respond to existing therapies.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with immune checkpoint refractory or immune checkpoint naïve solid tumors. In addition, NextCure announced it has entered into a supply agreement for KEYTRUDA with Merck (known as MSD outside the United States and Canada).
As more life science companies flock to the region a new challenge arises – how do we create a strong pipeline of local talent to support their needs? This pipeline not only includes the high concentration of experienced talent the BHCR is known for but entry-level employees and people without four-year degrees who can be trained on-the-job.
NextCure (Nasdaq: NXTC), a growing clinical-stage biotechnology company nestled in Beltsville, Maryland, is setting the example. The company works to create novel immunomedicines to treat cancer and other immune-related diseases, and if you’ve read some of BioBuzz’s previous stories you should know by now that when NextCure says they are committed to something, they truly are committed.
(Photo Credit: NextCure) Quality Culture Runs Deep at NextCure For many companies, Quality is only addressed out in the open after something goes wrong. By then, it’s often too late [….]
